PubMed Health⌕ Search

PubMed · 11690109

Fluctuation-dominated phase ordering driven by stochastically evolving surfaces: depth models and sliding particles.

Abstract

We study an unconventional phase ordering phenomenon in coarse-grained depth models of the hill-valley profile of fluctuating surfaces with zero overall tilt, and for hard-core particles sliding on such surfaces under gravity. We find that several such systems approach an ordered state with large scale fluctuations which make them qualitatively different from conventional phase ordered states. We consider surfaces in the Edwards-Wilkinson (EW), Kardar-Parisi-Zhang (KPZ) and noisy surface-diffusion (NSD) universality classes. For EW and KPZ surfaces, coarse-grained depth models of the surface profile exhibit coarsening to an ordered steady state in which the order parameter has a broad distribution even in the thermodynamic limit, the distribution of particle cluster sizes decays as a power-law (with an exponent straight theta), and the scaled two-point spatial correlation function has a cusp (with an exponent alpha=1/2) at small values of the argument. The latter feature indicates a deviation from the Porod law which holds customarily, in coarsening with scalar order parameters. We present several numerical and exact analytical results for the coarsening process and the steady state. For linear surface models with a dynamical exponent z, we show that alpha=(z-1)/2 for z<3 and alpha=1 for z>3, and there are logarithmic corrections for z=3, implying alpha=1/2 for the EW surface and 1 for the NSD surface. Within the independent interval approximation we show that alpha+straight theta=2. We also study the dynamics of hard-core particles sliding locally downward on these fluctuating one-dimensional surfaces, and find that the surface fluctuations lead to large-scale clustering of the particles. We find a surface-fluctuation driven coarsening of initially randomly arranged particles; the coarsening length scale grows as approximately t(1/z). The scaled density-density correlation function of the sliding particles shows a cusp with exponents alpha approximately 0.5 and 0.25 for the EW and KPZ surfaces. The particles on the NSD surface show conventional coarsening (Porod) behavior with alpha approximately 1.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D Das, M Barma, S N Majumdar. 2001-09-25. Fluctuation-dominated phase ordering driven by stochastically evolving surfaces: depth models and sliding particles.. https://doi.org/10.1103/physreve.64.046126

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗